US20110189203A1 - Immunoglobulin constructs - Google Patents

Immunoglobulin constructs Download PDF

Info

Publication number
US20110189203A1
US20110189203A1 US12/745,023 US74502308A US2011189203A1 US 20110189203 A1 US20110189203 A1 US 20110189203A1 US 74502308 A US74502308 A US 74502308A US 2011189203 A1 US2011189203 A1 US 2011189203A1
Authority
US
United States
Prior art keywords
single variable
directed against
antigen
target
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/745,023
Other languages
English (en)
Inventor
Guy Hermans
Hilde Adi Pierrette Revets
Michael John Scott Saunders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Priority to US12/745,023 priority Critical patent/US20110189203A1/en
Assigned to ABLYNX N.V. reassignment ABLYNX N.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SAUNDERS, MICHAEL JOHN SCOTT, HERMANS, GUY, REVETS, HILDE ADI PIERRETTE
Publication of US20110189203A1 publication Critical patent/US20110189203A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to protein and polypeptide constructs that comprise single variable domains that are linked to an Fc portion.
  • the immunoglobulin single variable domains may for example be a domain antibody (or an immunoglobulin variable domain that is suitable for use as a domain antibody), a single domain antibody (or an immunoglobulin variable domain that is suitable for use as a single domain antibody), a “dAb” (or an immunoglobulin variable domain that is suitable for use as a dAb) or a Nanobody (as defined herein, and including but not limited to a V HH sequence); or any suitable fragment of any one thereof.
  • the invention also relates to polypeptide chains that form part of such constructs and/or that can be used to form such constructs.
  • the invention further relates to nucleotide sequences and nucleic acids that encode or can be used to express such constructs or polypeptide chains; to methods for producing such constructs and polypeptides chains; to compositions (and in particular pharmaceutical compositions) that comprise such constructs or polypeptide chains; and to uses of such constructs, polypeptide chains or compositions.
  • V HH domains naturally occurring single variable domains
  • these heavy chain antibodies lack the C H 1 domain that is present in conventional 4-chain antibodies, with the V HH being directly linked—via the hinge—to the C H 2 domain of the Fc portion.
  • EP 0 698 097 and its divisional application EP 1 621 554 also describe that V HH domains can be linked to a human Fc portion.
  • WO 04/068820 describes so-called “dAb's” that are linked to an effector group.
  • the examples given are constructs that comprise dAb's linked to the Fc of IgG1.
  • constructs described in EP 1 621 554 and WO 04/068820 comprise two polypeptide chains, in which each polypeptide chain comprises one single variable domain that is linked, usually via a suitable hinge region or linker, to two constant domains that, in the final construct, form the Fc portion. These constructs bind to the intended antigen via the two antigen-binding sites that are formed by each of the single variable domains.
  • WO 02/056910 describes constructs in which binding domains that include at least one immunoglobulin variable region polypeptide are linked, via a suitable linker, to C H 2/C H 3 constant regions.
  • the immunoglobulin variable region polypeptide may be all or a portion or fragment of heavy chain or light chain V-region, provided it is capable of specifically binding an antigen.
  • WO 02/056910 further gives examples of constructs in which the immunoglobulin variable region polypeptide is comprised of an ScFv fragment. These constructs therefore comprise two polypeptide chains, in which each polypeptide chain comprises two variable domains (i.e.
  • each variable domain is a single variable domain (meaning that it forms a functional antigen binding unit or site without requiring interaction with another variable domain).
  • the present invention provides immunoglobulin constructs that comprise two polypeptide chains (each, a “polypeptide chain of the invention”), in which each polypeptide chain comprises two or more single variable domains that are linked, usually via a suitable hinge region or linker, to one or more constant domains that, in the final construct, together form an Fc portion.
  • constructs provided by the invention generally comprise an Fc portion (as defined herein) in which each of the two polypeptide chains that form the Fc portion is linked, optionally via a suitable linker or hinge region, to two or more single variable domains (also as defined herein).
  • Such constructs may for example be as described in EP 1 621 554 or WO 02/056910, but with one or more additional single variable domains linked to each single variable domain that is already present in the constructs described in these references.
  • polypeptide chains of the invention and their use in forming the constructs of the invention, form further aspects of the invention. Also, in one specific aspect of the invention, as further described herein, these polypeptide chains of the invention may also be used as such (i.e. without interaction with another polypeptide chain and/or not as part of a construct of the invention).
  • each polypeptide chain of the invention comprises two or three single variable domains, and more preferably only two single variable domains.
  • the constructs of the invention preferably comprise a total of six single variable domains (i.e. three in each polypeptide chain) and more preferably a total of four single variable domains (i.e. two in each polypeptide chain).
  • each polypeptide chain of the invention will usually comprise either two constant domains (for example, in case of an Fc portion that is derived from IgG, IgA or IgD) or three constant domains (for example, in ease of an Fc portion that is derived from IgM or IgE), such that, in the final construct, the constant domains of the two polypeptide chains form an Fc portion, for example an Fc portion that is derived from IgG (e.g. IgG1, IgG2, IgG3 or IgG4), IgA, IgD, IgE or IgM, or a variant, analog, mutant, part or fragment thereof (including chimeric Fc portions), that may or may not have effector functions, as further described herein.
  • IgG e.g. IgG1, IgG2, IgG3 or IgG4
  • IgA, IgD, IgE or IgM or a variant, analog, mutant, part or fragment thereof (including chimeric Fc portions
  • constructs that comprise a total of four single variable domains (i.e. two in each polypeptide chain) and four constant domains (i.e. two in each polypeptide chain), in which the variable domains are linked to each other via a suitable linker and are linked to the constant domains via a suitable linker or hinge region.
  • the teaching of the present invention can equally be applied to constructs of the invention that comprise six or even more single variable domains (i.e.
  • variable domains in each polypeptide chain and/or that comprise six constant domains (for example, in case of an Fc portion that is derived from IgM or IgE), and/or in which the constant domains are directly linked to each other and/or directly linked to the constant domains (for example, when the Fc portion is derived from IgE, a hinge region between the Fc portion and the variable domains may not be required).
  • each polypeptide chain of the invention comprises two constant domains that are capable, together with the constant domains that are present in the other polypeptide chain that forms part of the construct, to form an Fc portion (as defined herein).
  • These constant domains are linked (optionally via a suitable linker or hinge region) to a “first” single variable domain, which first single variable domain is linked (again optionally via a suitable linker) to a “second” single variable domain (which may in turn be linked, again optionally via a suitable linker, to a “third” single variable domain, and so forth).
  • Constructs of the invention with four single variable domains and four constant domains are schematically shown in the non-limiting FIG. 1 .
  • the constructs comprise two polypeptide chains ( 1 ) and ( 2 ), which each comprise two constant domains ( 7 ) and ( 8 ), a “first” single variable domain ( 3 ) and a “second” single variable domain ( 4 ).
  • the first single variable domain ( 3 ) is linked, optionally via a suitable linker ( 5 ), to the second single variable domain ( 4 ), and is also linked to the constant domains, optionally (and usually) via a suitable linker or hinge region ( 6 ).
  • the constant domains ( 7 ) and ( 8 ) of the polypeptide chain ( 1 ) and the corresponding constant domains ( 7 ) and ( 8 ) of the polypeptide chain ( 2 ) together form the Fc portion ( 9 ).
  • Constructs of the invention with four single variable domains and six constant domains are schematically shown in the non-limiting FIG. 2 .
  • the constructs comprise two polypeptide chains ( 1 ) and ( 2 ), which each comprise three constant domains ( 7 ), ( 8 ) and ( 10 ), a “first” single variable domain ( 3 ) and a “second” single variable domain ( 4 ).
  • the first single variable domain ( 3 ) is linked, optionally via a suitable linker ( 5 ), to the second single variable domain ( 4 ), and is also linked to the constant domains, optionally (and usually) via a suitable linker or hinge region ( 6 ).
  • FIG. 3 shows a constructs of the invention with six single variable domains and four constant domains (for example forming an Fc portion derived from an IgG or IgA, or an analog, mutant or variant thereof).
  • the construct comprise two polypeptide chains ( 1 ) and ( 2 ), which each comprise two constant domains ( 7 ) and ( 8 ), a “first” single variable domain ( 3 ), a “second” single variable domain ( 4 ) and a “third” single variable domain ( 11 ).
  • the first single variable domain ( 3 ) is linked, optionally via a suitable linker ( 5 ), to the second single variable domain ( 4 ), and is also linked to the constant domains, optionally (and usually) via a suitable linker or hinge region ( 6 ).
  • the third first single variable domain ( 11 ) is linked, optionally via a suitable linker ( 12 ), to the second single variable domain ( 4 ).
  • the constant domains ( 7 ) and ( 8 ) of the polypeptide chain ( 1 ) and the corresponding constant domains ( 7 ) and ( 8 ) of the polypeptide chain ( 2 ) together form the Fc portion ( 9 ).
  • each chain ( 1 ) and ( 2 ) can contain one or more additional single variable domains (not shown), which can be linked to the third single variable domain ( 11 ) and to each other, again optionally via suitable linkers.
  • FIG. 4 schematically shows a non-limiting example of a polypeptide of the invention, comprising two single variable domains and two constant domains.
  • the polypeptide comprises two constant domains ( 7 ) and ( 8 ), a “first” single variable domain ( 3 ) and a “second” single variable domain ( 4 ).
  • the first single variable domain ( 3 ) is linked, optionally via a suitable linker ( 5 ), to the second single variable domain ( 4 ), and is also linked to the constant domains, optionally (and usually) via a suitable linker or hinge region ( 6 ).
  • a polypeptide chain may be used to form a construct of the invention (i.e. with another polypeptide chain of the invention), but may also be used as such (i.e. without interaction with another polypeptide chain of the invention), for example when the Fc chain that is formed by the constant domains is monomeric (i.e. non self-associating).
  • all of the single variable domains that are present in the construct may each be directed against a different target, antigen, antigenic determinant or epitope.
  • this is generally less preferred.
  • both of the “first” single variable domains that are present in each of the polypeptide chain are directed against the same target or antigen
  • both of the “second” single variable domains that are present in each of the polypeptide chain are directed against the same target or antigen (and so on for the “third” and further single variable domains).
  • the first single variable domains and second single variable domains may be directed against a different target or antigen (such that the constructs of the invention are capable of simultaneously binding to two different targets or antigens); or may be directed against the same target or antigen (such that all single variable domains present in the construct are capable of binding to the same target or antigen).
  • two or more single variable domains in a construct of the invention when they are capable of binding to the same target or antigen, they may bind to the same epitope, antigenic determinant, part, domain or subunit of the target or antigen, or to different epitopes, antigenic determinants, parts, domains or subunits of the target or antigen.
  • both of the first single variable domains will bind to the same epitope, antigenic determinant, part, domain or subunit of the first target or antigen, and both the second single variable domains will bind to the same epitope, antigenic determinant, part, domain or subunit of the second target or antigen (although the invention in its broadest sense is not limited thereto).
  • both of the first single variable domains will bind to the same epitope, antigenic determinant, part, domain or subunit of the target or antigen
  • both of the second single variable domains will bind to the same epitope, antigenic determinant, part, domain or subunit of the target or antigen (although the invention in its broadest sense is again not limited thereto, and for example also comprises constructs in which each of the single variable domains can bind to a different epitope, antigenic determinant, part, domain or subunit of the target or antigen).
  • first single variable domains and the second single variable domains may bind to the same epitope, antigenic determinant, part, domain or subunit on the target or antigen, or may bind to different epitopes, antigenic determinants, parts, domains or subunits of the target or antigen.
  • the constructs of the invention comprise an Fc portion that is linked (optionally via a suitable linker or hinge region) to a pair of first single variable domains (i.e. one linked to each polypeptide chain that forms the Fc portion, as further described herein), which are linked (optionally via a suitable linker) to a pair of second single variable domains, wherein the constructs and the single variable domains present therein are such that:
  • constructs of the invention and the single variable domains present therein may be such that:
  • constructs of the invention may be capable of binding two different targets or antigens simultaneously.
  • constructs of the invention and the single variable domains present therein may be such that:
  • constructs of the invention may be capable of binding to the relevant target or antigen with greater avidity than a comparable construct that comprises only one pair of single variable domains (e.g. as described in EP 1 621 554 or WO 04/068820)
  • constructs of the invention and the single variable domains present therein may be such that:
  • constructs of the invention may be capable of binding to the relevant target or antigen with greater avidity than a comparable construct that comprises only one pair of single variable domains (e.g. as described in EP 1 621 554 or WO 04/068820).
  • the first variable domains may be directed against an “interaction site” on the target or antigen (i.e. a site for ligand binding, a catalytic site, a cleavage site, a site for allosteric interaction, a site involved in homodimerization or heterodimerization of the target or antigen; or any other site, epitope, antigenic determinant, part, domain or stretch of amino acid residues on the target or antigen that is involved in a biological action or mechanism of the target or antigen); and the second single variable domains may be directed against another site, epitope, antigenic determinant, part, domain or stretch of amino acid residues on the target or antigen that is not an interaction site (or visa versa).
  • an interaction site i.e. a site for ligand binding, a catalytic site, a cleavage site, a site for allosteric interaction, a site involved in homodimerization or heterodimerization of the target or antigen; or any other site
  • FIG. 9A and SEQ ID NO: 9 A non-limiting example of such a construct is given in FIG. 9A and SEQ ID NO: 9, which constructs comprises one Nanobody (121A2 p19+) that can bind to the p19 subunit of IL-23 and that can modulate (and in particular, reduce) binding of IL-23 to its receptor, and one Nanobody (81 G2 p19 ⁇ ) that can bind to the p19 subunit of IL-23 but that does not modulate binding of IL-23 to its receptor.
  • Nanobody 121A2 p19+
  • 81 G2 p19 ⁇ Nanobody that can bind to the p19 subunit of IL-23 but that does not modulate binding of IL-23 to its receptor.
  • variable domains may be directed against an interaction site on the target or antigen
  • the second variable domains may be directed against different interaction site on the target or antigen.
  • such constructs Besides binding to the target or antigen with increased avidity, such constructs have the further advantage that they are capable of modulating (as defined herein) two different mechanisms of action of the target or antigen simultaneously.
  • a construct of the invention may be directed against HER-2.
  • a construct of the invention that is directed against HER-2 in a construct of the invention that is directed against HER-2
  • constructs of the invention that are directed against tumor cells or tumor antigens may comprise an Fc portion that is derived from IgG (e.g. an IgG1, IgG2, IgG3 or IgG4) or IgA (or, less preferred, even IgM, IgD); but according to one specific aspect of the invention comprise an “IgE-derived Fc portion” (i.e. an Fc portion that is derived from IgE) as described in the co-pending International patent application of Ablynx N. V. entitled “Constructs comprising single variable domains and an Fc portion derived from IgE”, which has the same filing date as the present application.
  • constructs of the invention and the single variable domains present therein may be such that:
  • such constructs of the invention may not only be capable of binding to the relevant target or antigen with greater avidity than a comparable construct that comprises only one pair of single variable domains (e.g. as generally described in EP 1 621 554 or WO 04/068820, without reference to HER-2 as a possible target or antigen), but may also have improved selectivity, in particular when either the first and/or the second subunit is common between different heteromeric targets and antigens, as is for example the case for heterodimeric cytokines such as IL-12, IL-23, IL-27 and IL-35 (see Collson et al., Nature, Vol. 450, 22 Nov.
  • a construct of the invention may be directed against a heteromeric cytokine, and in particular against a heterodimeric cytokine of the IL-12 family, such as IL-12, IL-23, IL-27 or IL-35.
  • a construct of the invention may comprise first single variable domains that are directed against IL12p40, IL12p35, IL23p19, EBI3 or IL27p28, and second single variable domains that are directed against the same subunit or against another subunit that is present in a heteromeric cytokine, and in particular against a heterodimeric cytokine of the IL-12 family.
  • first and single variable domains are directed against the same subunit, they may for example:
  • the first and second single variable domains are directed against different subunits.
  • the first single variable domains may be directed against a subunit chosen from p19, p35 and p28, and the second single variable domains may be directed against a subunit chosen from p40 and EBI3 (or visa versa).
  • the first single variable domains may be directed against a subunit chosen from p19, p35 and p28
  • the second single variable domains may be directed against a subunit chosen from p40 and EBI3 (or visa versa).
  • such constructs are further preferably such that they are capable of binding to both of the subunits against which they are directed, more preferably essentially simultaneously so as to allow binding with increased avidity and specificity.
  • the above constructs are generally capable of modulating the heterodimeric cytokine(s) against which they are directed. Also, depending on the Fc portion present (as further described herein), the above constructs against heterodimeric cytokines may or may not have one or more effector functions.
  • the constant domains are suitably linked to the single variable domains, either directly (which is less preferred), via a suitable hinge region or linker (which is most preferred), or even (although much less preferred) via a suitable constant domain (such as a C ⁇ 1, C ⁇ 1, C ⁇ 1 or preferably C H 1 or C ⁇ 1 domain, which may in turn be linked to the Fc portion via a suitable linker).
  • a suitable constant domain such as a C ⁇ 1, C ⁇ 1, C ⁇ 1 or preferably C H 1 or C ⁇ 1 domain, which may in turn be linked to the Fc portion via a suitable linker.
  • the hinge region or linker may be any suitable hinge region or linker, and suitable hinge regions and linkers, which will usually comprise or essentially consist of a suitable amino acid sequence, will be clear to the skilled person based on the disclosure herein.
  • suitable hinge regions that naturally occur in immunoglobulins such as the hinge region of IgG's or the hinge region from Camelid heavy chain antibodies, see for example EP 0 698 097 or the linkers described in WO 96/34103
  • suitable analogs, variants, homologs, parts or fragments thereof including synthetic or semi-synthetic analogs, variants, homologs, parts or fragments, for example hinge regions that have been engineered so as not to contain cysteine residues, see for example WO 07/085,814), as well as the synthetic and semi-synthetic linkers mentioned in WO 04/068820 and WO 02/056910, as well as the linkers that are mentioned in WO 06/122 825 for linking Nanobodies in multivalent Nano
  • a naturally occurring CJ domain or a suitable variant thereof may be used as (or instead of) a hinge region.
  • a nucleotide sequence encoding a hinge from a Camelid heavy chain antibody is given in Table 1 (SEQ ID NO: 14) below.
  • the first and second (and optionally third and further) single variable domains are also suitably linked to each other, either directly (which is less preferred) or via a suitable hinge regions or linkers (which is most preferred), or even (although much less preferred) via a suitable constant domain.
  • Suitable linkers will be clear to the skilled person based on the disclosure herein, and include the linkers and hinge regions mentioned above for linking the single variable domains to the constant domains, the synthetic and semi-synthetic linkers mentioned in WO 04/068820 and WO 02/056910, the linkers that are mentioned in WO 06/122 825 for linking Nanobodies in multivalent Nanobody constructs, as well as the spacers and linkers that are used in the art to link antibody fragments or antibody domains. These include the linkers mentioned in the general background art cited herein, as well as for example linkers that are used in the art to construct diabodies or ScFv fragments.
  • the linker may be a suitable amino acid sequence, and in particular amino acid sequences of between 1 and 60, preferably between 15 and 50, such as between 20 and 40 amino acid residues, such as about 25, 30 or 40 amino acid residues (depending on the amino acid composition of the linker).
  • gly-ser linkers for example of the type (gly x ser y ) z , such as (for example (gly 4 ser) 3 or (gly 3 ser 2 ) 3 , as described in WO 99/42077 and the GS30, GS15, GS9 and GS7 linkers described in the applications by Ablynx mentioned herein (see for example WO 06/040153 and WO 06/122825), as well as hinge-like regions, such as the hinge regions of naturally occurring heavy chain antibodies or similar sequences (such as described in WO 94/04678).
  • gly-ser linkers for example of the type (gly x ser y ) z , such as (for example (gly 4 ser) 3 or (gly 3 ser 2 ) 3 , as described in WO 99/42077 and the GS30, GS15, GS9 and GS7 linkers described in the applications by Ablynx mentioned herein (see for example WO 06/040153 and WO 06/1228
  • linkers GS9 SEQ ID NO: 84 in WO 06/122825
  • linkers GS30 SEQ ID NO: 85 in WO 06/122825
  • GS 35 used in the constructs of SEQ ID NO's: 1 to 8.
  • the constructs of the invention are preferably such that both the first single variable domains and the second single variable domains are capable of binding to their intended or respective target, antigen, epitope, antigenic determinant, part, domain or subunit, more preferably essentially simultaneously, so as to allow binding with higher avidity (and, where relevant, higher specificity or with other advantages that can be obtained through the use of the constructs of the invention).
  • the skilled person will be able to choose suitable linkers for this purpose, optionally using in silico techniques for molecular modelling and/or a limited degree of experimentation.
  • the invention relates to the polypeptide chains of the invention, and to nucleic acids encoding the same.
  • Such polypeptide chains of the invention may further be as described herein for the construct of the invention, albeit that they consist of a single polypeptide chain with two or more single variable domains and one or more (such as two or three) constant domains that are capable (together with the constant domains of another polypeptide chain of the invention, to form an Fc portion (as further described herein).
  • polypeptide chains may:
  • polypeptide chains of the invention will usually be used as part of, and/or to form, a construct of the invention, as further described herein.
  • the constant domains used in a polypeptide chain of the invention may be such that they allow the polypeptide chain of the invention to be used (i.e. for antigen-binding, for example for therapeutic purposes) as such, i.e. without forming part of a construct of the invention.
  • the constant domains may be naturally occurring, synthetic or semisynthetic analogs, variants, parts or fragments of constant domains that, when combined in a polypeptide chain of the invention, confer upon the polypeptide chain a reduced (or essentially no) tendency to self-associate into dimmers (i.e. compared to the constant domains that naturally occur in the native Fc portion).
  • Such monomeric (i.e. not self-associating) Fc chain variants, or fragments thereof will be clear to the skilled person.
  • Helm et al. J Biol Chem 1996 271 7494
  • monomeric Fc ⁇ chain variants that can be used in the polypeptide chains of the invention.
  • such monomeric Fc chain variants are preferably such that they are still capable of binding to the complement or the relevant Fc receptor(s) (depending on the Fc portion from which they are derived), and/or such that they still have some or all of the effector functions of the Fc portion from which they are derived (or at a reduced level still suitable for the intended use).
  • the monomeric Fc chain may be used to confer increased half-life upon the polypeptide chain, in which case the monomeric Fc chain may also have no or essentially no effector functions.
  • the first single variable domains will be essentially the same (i.e. be comprised of essentially the same amino acid sequence) in both polypeptide chains that form the construct of the invention, and the second single variable domain will be essentially the same in both polypeptide chains that form the construct of the invention (although the invention in its broadest sense is not limited thereto).
  • the constant domains that are present in both of the polypeptide chains that form the construct of the invention will be essentially the same (i.e. be comprised of essentially the same amino acid sequence).
  • both polypeptide chains that form the construct of the invention will comprise essentially the same first, second (and optionally third and further) single variable domains and essentially the same constant domains, so that the constructs of the invention will usually be comprised of two polypeptide chains that have essentially the same (variable and constant) domains and thus essentially the same sequence.
  • the invention in its broadest sense is not limited thereto, and for example also comprises constructs in which either or both of the first and/or the second (and/or optionally the third or further) variable domains are not the same in the two polypeptide chains that from the construct of the invention; as well as constructs in which the two polypeptide chains that form the construct of the invention comprise different hinge regions or linkers; and even constructs in which the two polypeptide chains that form the construct of the invention comprise different constant domains (as long as the constant domains of the two polypeptide chains are still capable of forming an Fc portion, as defined herein).
  • the invention relates to an immunoglobulin construct is directed against an intended or desired antigen, which immunoglobulin construct comprises an Fc portion and at least four (such as six and preferably four) single variable domains, which immunoglobulin construct is capable of binding to the desired or intended antigen with at least four (such as all six or all four) single variable domains.
  • the single variable domains present in the construct when directed against the same target or antigen, they may be directed against the same antigenic determinant, epitope, part or domain on the target (in particular, for example, when the target is a multimeric target, so that the same antigenic determinant, epitope, part or domain occurs multiple times in the multimer), against different antigenic determinants, epitopes, parts or domains on the target, or (when the target is a heteromeric protein comprising two or more different subunits) against different subunits of the target.
  • a construct of the invention that is directed against a desired or intended target or antigen may be comprised of two polypeptide chains, in which each polypeptide chain comprises one or more (and usually two or three) constant domains (that are capable, together with the constant domains that are present in the other polypeptide chain, to form an Fc portion), that is linked (optionally via a suitable linker or hinge region) to a “first” single variable domain that is directed against a first epitope, antigenic determinant, part, domain or subunit of the target or antigen, which first single variable domain is linked (again optionally via a suitable linker) to a “second” single variable domain that is directed against a second epitope, antigenic determinant, part, domain or subunit of the target or antigen (which may in turn be linked, again optionally via a suitable linker, to a “third” single variable domain that is directed against a third epitope, antigenic determinant, part, domain or subunit
  • first and second (and optionally third or further) single variable domains are directed against the same epitope, antigenic determinant, part, domain or subunit, they may have essentially the same sequence (which will usually be preferred in practice) or have different sequences.
  • first and second (and optionally third or further) single variable domains are directed against different epitopes, antigenic determinants, parts, domains or subunits, they will as a rule have different sequences.
  • the first single variable domain will preferably be the essentially same (i.e. be comprised of essentially the same amino acid sequence) in both polypeptide chains that form the construct of the invention
  • the second single variable domain will preferably be essentially the same in both polypeptide chains that form the construct of the invention
  • the constant domains will preferably be essentially the same in both polypeptide chains that form the construct of the invention (so that, again, the constructs of the invention will be comprised of two polypeptide chains that have essentially the same (variable and constant) domains and more in particular essentially the same sequence).
  • the constructs of the invention are directed towards a multimeric target or antigen (such as a dimeric target or trimeric target), and the first and second (and optionally third or further) single variable domains are directed against the same epitope, antigenic determinant, part or domain, and preferably have essentially the same sequence.
  • a multimeric target or antigen such as a dimeric target or trimeric target
  • the first and second (and optionally third or further) single variable domains are directed against the same epitope, antigenic determinant, part or domain, and preferably have essentially the same sequence.
  • the constructs of the invention are directed towards a heteromeric target or antigen (for example comprised of two or three different subunits), and the first single variable domain is directed against a first subunit of the target or antigen and the second single variable domain is directed against a second subunit of the target or antigen.
  • a heteromeric target or antigen for example comprised of two or three different subunits
  • the first single variable domains may be directed against different antigenic determinants, epitopes, parts or domains or subunits of the same target, and the second and further single variable domains may or may not be present.
  • the constructs of this particular aspect of the invention only comprise two single variable domains, which are directed against different antigenic determinants, epitopes, parts or domains or subunits of the same target.
  • such a construct, and in particular the linkers or hinge region that link the single variable domains to the constant domain(s), is preferably such that both of the first single variable domains are capable of binding to their intended or respective epitope, antigenic determinant, part, domain or subunit, more preferably essentially simultaneously.
  • the constant domains that are present in each of the polypeptide chains that form a construct of the invention should be such that they are capable of forming an Fc portion with the constant domains that are present in the other polypeptide chain that forms the construct of the invention.
  • the constant domains that are present in both of the polypeptide chains that form the construct of the invention will in practice usually be essentially the same (i.e. be comprised of essentially the same amino acid sequence).
  • the constant domains may be C H 2 and C H 3 domains that are capable of forming an IgG Fc portion (e.g.
  • an IgG1, IgG2, IgG3 or IgG4 Fc portion C ⁇ 2 and C ⁇ 3 domains that are capable of forming an IgA Fc portion, C ⁇ 2 and C ⁇ 3 that are capable of forming an IgD Fc portion, C ⁇ 2, C ⁇ 3 and C ⁇ 4 domains that are capable of forming an IgM Fc portion; or C ⁇ 2, C ⁇ 3 and C ⁇ 4 domains that are capable of forming an IgE Fc portion.
  • the constant domains may also be such that they are capable of forming a chimeric Fc portion.
  • the constant domains are constant domains that are derived from human antibodies, so that the Fc portion is the Fc portion of a human IgG (e.g. an IgG1, IgG2, IgG3 or IgG4), IgA, IgM, IgD or IgE, or a chimeric constant domain that is fully comprised of human constant domains.
  • a human IgG e.g. an IgG1, IgG2, IgG3 or IgG4
  • IgA, IgM, IgD or IgE a chimeric constant domain that is fully comprised of human constant domains.
  • nucleotide sequences encoding the CH 2 and CH 3 domains of human IgG1 are given in Table 1 (SEQ ID NOs: 12 and 13) below.
  • the constant domains may also be suitable parts, fragments, analogs, variants or mutants of the aforementioned constant domains, as long as they are capable of forming an Fc portion and preferably are further such that they are still capable of providing their desired effector functions.
  • the constant domains that form the Fc portion are preferably essentially comprised of human constant domains or of amino acid sequences that are derived from human constant domains.
  • the specific constant domain(s) and/or Fc portion chosen will depend upon the intended use and properties (such as effector functions) of the final construct, and may be suitably chosen so as to provide the desired properties (for example, binding and/or activating complement, the ability to trigger ADCC, the ability to trigger other immune responses, and/or other desired effector functions) or to avoid such properties. Based on the disclosure herein, a skilled person will be able to choose a suitable Fc portion for a specific purpose or application. Usually, IgG-derived Fc portions (such as IgG1, IgG2, IgG3 or IgG4-derived. Fc portions) will be preferred.
  • constructs of the invention when directed against tumor cells or tumor antigens (such as HER-2), they may also comprise an “IgE-derived Fc portion” (i.e. an Fc portion that is derived from IgE) as described in the co-pending International patent application of Ablynx N. V, entitled “Constructs comprising single variable domains and an Fc portion derived from IgE”, which has the same filing date as the present application.
  • IgE-derived Fc portion i.e. an Fc portion that is derived from IgE
  • the Fc portion may also (be used to) confer upon the constructs the invention an increased half-life in vivo.
  • the Fc portion may still have some or all of its effector functions (or have these effector functions, but at a reduced level still suitable for the intended use), but when the Fc portion is solely used to provide for increased half-life, also a suitable mutant, variant part or fragment of an Fc portion may be used that has no or essentially no effector functions.
  • Half-life can generally be defined as the time taken for the serum concentration of the polypeptide to be reduce by 50%, in viva, for example due to degradation of the ligand and/or clearance or sequestration of the ligand by natural mechanisms.
  • the constructs or polypeptides of the invention may have a half-life in a mammal (such as a mouse, rat or monkey) and/or in man that is at least 25%, preferably at least 50%, more preferably at least 70%, such as about 80% or 90% or more, of a naturally occurring IgE in said mammal or in man.
  • the invention also relates to a protein or polypeptide that comprises or essentially consists of a construct of the invention.
  • the invention further relates to a polypeptide chain that forms part of a construct of the invention and/or that is capable of forming (or can be used to form) a construct of the invention (i.e. together with another such polypeptide chain), which. polypeptide chain is as further described herein.
  • the invention further relates to nucleotide sequences or nucleic acids that encode and/or that can be used to express a construct of the invention and/or a polypeptide chain of the invention.
  • nucleotide sequences or nucleic acids which are also generally referred to herein as “nucleic acids of the invention” may be as further described herein.
  • the invention further relates to methods for producing the constructs and polypeptides of the invention; to compositions (and in particular pharmaceutical compositions) that comprise one or more constructs or polypeptide chains of the invention; and to uses of the constructs or polypeptide chains of the invention or of compositions comprising them. Such methods, compositions and uses may be as further described herein.
  • modulating or “to modulate” generally means either reducing or inhibiting the activity of, or alternatively increasing the activity of, a target or antigen, as measured using a suitable in vitro, cellular or in vivo assay.
  • modulating or “to modulate” may mean either reducing or inhibiting the activity of, or alternatively increasing a (relevant or intended) biological activity of, a target or antigen, as measured using a suitable in vitro, cellular or in vivo assay (which will usually depend on the target or antigen involved), by at least 1%, preferably at least 5%, such as at least 10% or at least 25%, for example by at least 50%, at least 60%, at least 70%, at least 80%, or 90% or more, compared to activity of the target or antigen in the same assay under the same conditions but without the presence of the construct of the invention.
  • “modulating” may also involve effecting a change (which may either be an increase or a decrease) in affinity, avidity, specificity and/or selectivity of a target or antigen for one or more of its ligands, binding partners, partners for association into a homomultimeric or heteromultimeric form, or substrates; and/or effecting a change (which may either be an increase or a decrease) in the sensitivity of the target or antigen for one or more conditions in the medium or surroundings in which the target or antigen is present (such as pH, ion strength, the presence of co-factors, etc.), compared to the same conditions but without the presence of the construct of the invention.
  • this may again be determined in any suitable manner and/or using any suitable assay known per se, depending on the target or antigen involved.
  • Modulating may also mean effecting a change (i.e. an activity as an agonist, as an antagonist or as a reverse agonist, respectively, depending on the target or antigen and the desired biological or physiological effect) with respect to one or more biological or physiological mechanisms, effects, responses, functions, pathways or activities in which the target or antigen (or in which its substrate(s), ligand(s) or pathway(s) are involved, such as its signalling pathway or metabolic pathway and their associated biological or physiological effects) is involved.
  • a change i.e. an activity as an agonist, as an antagonist or as a reverse agonist, respectively, depending on the target or antigen and the desired biological or physiological effect
  • a change i.e. an activity as an agonist, as an antagonist or as a reverse agonist, respectively, depending on the target or antigen and the desired biological or physiological effect
  • a change i.e. an activity as an agonist, as an antagonist or as a reverse agonist, respectively, depending on the target or antigen and the desired biological or physiological effect
  • an action as an agonist or antagonist may be such that an intended biological or physiological activity is increased or decreased, respectively, by at least 1%, preferably at least 5%, such as at least 10% or at least 25%, for example by at least 50%, at least 60%, at least 70%, at least 80%, or 90% or more, compared to the biological or physiological activity in the same assay under the same conditions but without the presence of the construct of the invention.
  • Modulating may for example also involve allosteric modulation of the target or antigen; and/or reducing or inhibiting the binding of the target or antigen to one of its substrates or ligands and/or competing with a natural ligand, substrate for binding to the target or antigen. Modulating may also involve activating the target or antigen or the mechanism or pathway in which it is involved. Modulating may for example also involve effecting a change in respect of the folding or confirmation of the target or antigen, or in respect of the ability of the target or antigen to fold, to change its confirmation (for example, upon binding of a ligand), to associate with other (sub)units, or to disassociate. Modulating may for example also involve effecting a change in the ability of the target or antigen to transport other compounds or to serve as a channel for other compounds (such as ions).
  • Modulating may be reversible or irreversible, but for pharmaceutical and pharmacological purposes will usually be in a reversible manner.
  • the single variable domains that are present in the constructs of the invention may be any variable domain that forms a single antigen binding unit.
  • such single variable domains will be amino acid sequences that essentially consist of 4 framework regions (FR1 to FR4 respectively) and 3 complementarity determining regions (CDR1 to CDR3 respectively); or any suitable fragment of such an amino acid sequence (which will then usually contain at least some of the amino acid residues that form at least one of the CDR's, as further described herein).
  • Such single variable domains and fragments are most preferably such that they comprise an immunoglobulin fold or are capable for forming, under suitable conditions, an immunoglobulin fold.
  • the single variable domain may for example comprise a light chain variable domain sequence (e.g.
  • V L -sequence or a suitable fragment thereof; or a heavy chain variable domain sequence (e.g. a V H -sequence or V HH sequence) or a suitable fragment thereof; as long as it is capable of forming a single antigen binding unit (i.e. a functional antigen binding unit that essentially consists of the single variable domain, such that the single antigen binding domain does not need to interact with another variable domain to form a functional antigen binding unit or site, as is for example the case for the variable domains that are present in for example conventional antibodies and ScFv fragments that need to interact with another variable domain—e.g. through a V H /V L interaction—to form a functional antigen binding domain).
  • a single antigen binding unit i.e. a functional antigen binding unit that essentially consists of the single variable domain, such that the single antigen binding domain does not need to interact with another variable domain to form a functional antigen binding unit or site, as is for example the case for the variable domains that are present in
  • the single variable domain may be a domain antibody (or an amino acid sequence that is suitable for use as a domain antibody), a single domain antibody (or an amino acid sequence that is suitable for use as a single domain antibody), a “dAb” (or an amino acid sequence that is suitable for use as a dAb) or a Nanobody (as defined herein, and including but not limited to a V HH sequence); other single variable domains, or any suitable fragment of any one thereof.
  • dAb or an amino acid sequence that is suitable for use as a dAb
  • Nanobody as defined herein, and including but not limited to a V HH sequence
  • the amino acid sequence of the invention may be a NanobodyTM or a suitable fragment thereof.
  • NanobodyTM or a suitable fragment thereof.
  • WO 94/04678, WO 95/04079 and WO 96/34103 of the Vrije Universiteit Brussel WO 94/25591, WO 99/37681, WO 00/40968, WO 00/43507, WO 00/65057, WO 01/40310, WO 01/44301, EP 1134231 and WO 02/48193 of Unilever; WO 97/49805, WO 01/21817, WO 03/035694, WO 03/054016 and
  • Nanobodies in particular V I-114 sequences and partially humanized Nanobodies
  • the single variable domains used in the constructs of the invention may be directed against (as defined in WO 06/122 825) any suitable antigen.
  • suitable antigens and of single variable domains directed against those antigens will be clear to the skilled person based on the disclosure herein, and for example include the antigens and single variable domains mentioned in the prior art cited herein as well as the antigens and “dAb's” mentioned and described in the patent applications of Domantis Ltd. or Domantis Inc.
  • constructs of the invention may be prepared in any suitable manner known per se. Usually, such methods will either comprise joining two suitable polypeptide chains of the invention so as to form a construct of the invention (in which these polypeptide chains will usually be essentially identical in sequence, although the invention in its broadest sense is not limited thereto).
  • the polypeptide chains of the invention may be prepared in any suitable manner, usually by suitably expressing, in a suitable host or host organism, a nucleic acid of the invention that encodes the desired polypeptide chain.
  • constructs of the invention may be prepared by suitably co-expressing, in a suitable host or host organism, (suitable nucleic acids of the invention that encode) two suitable polypeptide chains of the invention (in which these polypeptide chains will again usually be essentially identical in sequence) so as to form a construct of the invention.
  • the nucleic acids encoding the polypeptide chains of the invention may be prepared in any suitable manner, for example using PCR assembly using overlapping primers, by suitably linking (naturally occurring, synthetic or semi-synthetic) nucleotide sequences that encode the various parts of the desired polypeptide chain, or by de novo synthesis of the desired nucleic acid of the invention using an automated apparatus for synthesizing nucleic acid sequences with a predefined amino acid sequence.
  • the particular codons used may also be chosen and/or optimized for the host or host organism to be used for the expression.
  • nucleic acids of the invention may be provided and/or used in the form of a suitable genetic construct (such as a plasmid or expression vector), that may for example comprise—in addition to the nucleotide sequences that encodes the desired polypeptide chain—one or more regulatory elements and/or other suitable components of such constructs known per se. All this can be performed using methods and techniques known per se, for which reference is made to the prior art cited herein, such as WO 04/068820 and WO 02/056910.
  • nucleotide sequences encoding the desired single variable domains can be suitably linked to a nucleotide sequence that encodes the desired constant domains, optionally via nucleotide sequences that encode suitable linkers or hinge regions as described herein.
  • the further expression, production, purification and isolation may be performed using techniques, vectors, host cells or host organisms known per se, for which reference is again made to for example WO 04/068820 and WO 02/056910.
  • the invention relates to a host or host cell that expresses or is capable of expressing a construct of the invention or a polypeptide chain of the invention, or that contains a nucleotide sequence or nucleic acid that encodes a construct of the invention or a polypeptide chain of the invention.
  • the invention further relates to methods for producing a construct of the invention or a polypeptide chain of the invention, comprising maintaining or cultivating such a host or host cell under conditions such that said host or host cell expresses or produces a construct of the invention or a polypeptide chain of the invention, and optionally comprising isolating the construct of the invention or polypeptide chain of the invention so expressed or produced.
  • compositions that comprise at least one construct of the invention or a polypeptide chain of the invention.
  • a composition may in particular be a pharmaceutical composition that comprises at least one construct of the invention and one or more pharmaceutically acceptable carriers, adjuvants or excipients.
  • a pharmaceutical composition will be a (usually liquid and aqueous) composition that is suitable for injection or infusion, essentially similar to the formulations that are used for injection or infusion of conventional monoclonal antibodies, but containing one or more constructs of the invention instead of a conventional 4-chain monoclonal antibody.
  • the constructs and compositions of the invention may be used for any suitable purpose, mainly depending upon the antigen(s) against which, the single variable domains that are present in the construct are directed.
  • the constructs and compositions of the invention may be used in the prevention and/or treatment of diseases and disorders that are associated with said target or antigen, i.e. by suitably administering the constructs or compositions to a subject that is at risk of and/or suffering from said disease or disorder.
  • diseases and disorders, and suitable routes of administration and treatment regimens will be clear to the skilled person based on the disclosure herein.
  • constructs of the invention can be made that are analogous to conventional therapeutic monoclonal antibodies (i.e. directed against the same target or antigen, but only containing two polypeptide chains as described herein, in which the single variable domains in each chain are directed against the relevant target or antigen), and that such constructs (and pharmaceutical compositions comprising the same) can be used for the prevention and/or treatment of essentially the same diseases and disorders as these conventional monoclonals, using essentially similar routes of administration and treatment regimens, which can easily be determined by the treating physician.
  • the invention relates to (the use of) a construct of the invention that is directed against a desired or intended (therapeutically relevant) target or antigen (or of a pharmaceutical composition comprising the same) for the prevention or treatment of a disease or disorder associated with said target or antigen.
  • the invention further relates to the use of a construct of the invention that is directed against a desired or intended (therapeutically relevant) target or antigen in the preparation of a pharmaceutical composition for the prevention or treatment of a disease or disorder associated with said target or antigen.
  • the invention also relates to a method for preventing or treating a disease or disorder that is associated with a target or antigen, which method comprises administering, to a subject in need of such prevention or treatment, of a therapeutically active amount of a construct of the invention that is directed against said target or antigen (or of a pharmaceutical composition comprising the same).
  • the construct of the invention is directed against HER-2.
  • Such constructs of the invention are particularly suited for the prevention and/or treatment of various forms of cancer and tumors (including solid tumors), e.g. by slowing, stopping or reversing the growth of a tumor and/or by slowing, stopping or reversing the spread of metastases caused by the tumor; and it is envisaged that such constructs of the invention may have improved efficacy and/or other improved properties compared to conventional 4-chain monoclonal antibodies against HER-2, such as for example Herceptin® or Omnitarg®.
  • the efficacy of the constructs of the invention that are directed against HER-2 may be determined using suitable cellular assays (for example using a suitable tumor cell line) or animal models known per se, which may be suitably chosen by the skilled person.
  • suitable constructs of the invention for use of the anti-HER-2 constructs of the invention in the prevention and/or treatment of cancer, suitable constructs of the invention, pharmaceutical compositions, routes of administration and treatment regimens will be clear to the skilled person based on the disclosure herein, and may for example also include suitable combination treatments with other cytostatic agents and/or with surgery and/or radiation treatment.
  • the invention relates to (the use of) a construct of the invention that is directed against HER-2 (or of a pharmaceutical composition comprising the same) for the prevention or treatment of cancer (and in particular, for the prevention or treatment of tumors that (over)express HER-2).
  • the invention further relates to the use of a construct of the invention that is directed against HER-2 in the preparation of a pharmaceutical composition for the prevention or treatment of cancer (and in particular, of tumors that express said tumor-associated target or antigen).
  • the invention also relates to a method for preventing or treating a cancer, which method comprises administering, to a subject in need of such prevention or treatment, of a therapeutically active amount of a construct of the invention that is directed against HER-2 or of a pharmaceutical composition comprising the same.
  • the construct of the invention is directed against a heterodimeric cytokine, such as against IL-12, IL-23, IL-27 or IL-35.
  • a heterodimeric cytokine such as against IL-12, IL-23, IL-27 or IL-35.
  • Such constructs of the invention are particularly suited for the prevention and/or treatment of a disease or disorder associated with said heterodimeric cytokine (i.e. with IL-12, IL-23, IL-27 and/or IL-35, respectively).
  • a disease or disorder associated with said heterodimeric cytokine i.e. with IL-12, IL-23, IL-27 and/or IL-35, respectively.
  • the invention relates to (the use of) a construct of the invention that is directed against a heterodimeric cytokine (or of a pharmaceutical composition comprising the same), such as against IL-12, IL-23, IL-27 or IL-35, for the prevention or treatment of a disease or disorder associated with said heterodimeric cytokine (i.e. with IL-12, IL-23, IL-27 and/or IL-35, respectively).
  • a heterodimeric cytokine or of a pharmaceutical composition comprising the same
  • a disease or disorder associated with said heterodimeric cytokine i.e. with IL-12, IL-23, IL-27 and/or IL-35, respectively.
  • the invention further relates to the use of a construct of the invention that is directed against a heterodimeric cytokine, such as against IL-12, IL-23, IL-27 or IL-35, in the preparation of a pharmaceutical composition for the prevention or treatment of a disease or disorder associated with said heterodimeric cytokine (i.e. with IL-12, IL-23, IL-27 and/or IL-35, respectively).
  • a heterodimeric cytokine such as against IL-12, IL-23, IL-27 or IL-35
  • the invention also relates to a method for preventing or treating a disease or disorder that is associated with a heterodimeric cytokine, such as with IL-12, IL-23, IL-27 or IL-35, which method comprises administering, to a subject in need of such prevention or treatment, of a therapeutically active amount of a construct of the invention that is directed against a heterodimeric cytokine, such as against IL-12, IL-23, IL-27 or IL-35 (or of a pharmaceutical composition comprising the same).
  • FIGS. 5 to 9 and Table 1 below give some non-limiting examples of amino acid sequences and nucleic acid sequences of polypeptide chains of the invention that can be used to form constructs of the invention:
  • FIGS. 9A to 9C give examples of constructs of the invention that are directed against IL-23.
  • the construct of FIG. 9A (SEQ ID NO:9) comprises one Nanobody (121A2 p19+) that can bind to the p19 subunit of IL-23 and that can modulate (and in particular, reduce) binding of IL-23 to its receptor, and one Nanobody (81G2 p19 ⁇ ) that can bind to the p19 subunit of IL-23 but that does not modulate binding of IL-23 to its receptor.
  • the construct of FIG. 9A comprises one Nanobody (121A2 p19+) that can bind to the p19 subunit of IL-23 and that can modulate (and in particular, reduce) binding of IL-23 to its receptor, and one Nanobody (81G2 p19 ⁇ ) that can bind to the p19 subunit of IL-23 but that does not modulate binding of IL-23 to its receptor.
  • 9B (SEQ ID NO:10) comprises one Nanobody (121A2 p19+) that can bind to the p19 subunit of IL-23 and that can modulate (and in particular, reduce) binding of IL-23 to its receptor, and one Nanobody (81E10 p40+) that can bind to the p40 subunit of IL-23 and that can modulate binding of IL-23 to its receptor.
  • IL-12 shares the p40 subunit with IL-23, it is expected that this construct can also bind to IL-12 (but with less avidity) and that this construct shows selectivity for IL-23 compared to IL-12.
  • FIG. 10 The construct of FIG.
  • 9C (SEQ ID NO:11) comprises one Nanobody (81E10 p40+) that can bind to the p40 subunit of IL-23 and that can modulate binding of IL-23 to its receptor, and one Nanobody (80D10) that can bind to the p40 subunit of IL-23 but that does not modulate binding of IL-23 to its receptor. Because IL-12 shares the p40 subunit with IL-23, it is expected that this construct can also bind to IL-12, also with improved avidity.
  • Non-limiting examples of amino acid sequences and nucleic acid sequences of polypeptide chains of the invention 47D5-35GS-2D3-hinge-CH2-CH3; SEQ ID NO: 1 kvqlvesggglvqpggslrlscaasgsifgfndmawyrqapgkqrelva lisrvgvtssadsvkgrftisrvnakdtvylqmnslkpedtavyycymd qrldgstlaywgqgtqvtvssggggsggggggsggggggggsggggggsggggggsggg gsggggsevqlvesggslvqpggslrlscaasgftfddyamswvrqvpg kglewvssinwsgthtdyadsvkgrftisrnnanntlylqmnslksedt avyy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US12/745,023 2007-11-27 2008-11-27 Immunoglobulin constructs Abandoned US20110189203A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/745,023 US20110189203A1 (en) 2007-11-27 2008-11-27 Immunoglobulin constructs

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US433207P 2007-11-27 2007-11-27
US533107P 2007-12-04 2007-12-04
US526507P 2007-12-04 2007-12-04
US532407P 2007-12-04 2007-12-04
US12/745,023 US20110189203A1 (en) 2007-11-27 2008-11-27 Immunoglobulin constructs
PCT/EP2008/066368 WO2009068630A1 (en) 2007-11-27 2008-11-27 Immunoglobulin constructs

Publications (1)

Publication Number Publication Date
US20110189203A1 true US20110189203A1 (en) 2011-08-04

Family

ID=40377235

Family Applications (5)

Application Number Title Priority Date Filing Date
US12/744,991 Active 2030-10-24 US8975382B2 (en) 2007-11-27 2008-11-27 Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US12/745,023 Abandoned US20110189203A1 (en) 2007-11-27 2008-11-27 Immunoglobulin constructs
US12/745,052 Abandoned US20110053865A1 (en) 2007-11-27 2008-11-27 Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US12/744,970 Abandoned US20110028695A1 (en) 2007-11-27 2008-11-28 Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US14/592,022 Active US9969805B2 (en) 2007-11-27 2015-01-08 Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/744,991 Active 2030-10-24 US8975382B2 (en) 2007-11-27 2008-11-27 Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12/745,052 Abandoned US20110053865A1 (en) 2007-11-27 2008-11-27 Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US12/744,970 Abandoned US20110028695A1 (en) 2007-11-27 2008-11-28 Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US14/592,022 Active US9969805B2 (en) 2007-11-27 2015-01-08 Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors

Country Status (12)

Country Link
US (5) US8975382B2 (ja)
EP (5) EP2215125A1 (ja)
JP (1) JP2011504740A (ja)
KR (1) KR20100097716A (ja)
CN (1) CN101970490A (ja)
AU (4) AU2008328779B2 (ja)
BR (1) BRPI0819656A2 (ja)
CA (4) CA2706200A1 (ja)
IL (1) IL205734A0 (ja)
MX (1) MX2010005783A (ja)
WO (5) WO2009068625A2 (ja)
ZA (1) ZA201004057B (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110028695A1 (en) * 2007-11-27 2011-02-03 Hilde Adi Pierrette Revets Method for obtaining polypeptide constructs comprising two or more single domain antibodies
WO2015160940A1 (en) * 2014-04-15 2015-10-22 President And Fellows Of Harvard College Bi-specific agents
WO2017015623A3 (en) * 2015-07-23 2017-03-23 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins
US11866507B2 (en) 2017-04-11 2024-01-09 Inhibrx, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same

Families Citing this family (256)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
HUE045710T2 (hu) 2005-05-18 2020-01-28 Ablynx Nv Javított, alfa tumor nekrózis faktor elleni nanobodies
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
MX2009009080A (es) 2007-02-23 2009-11-02 Schering Corp Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
TR201821029T4 (tr) 2007-02-23 2019-01-21 Merck Sharp & Dohme Geliştirilmiş antı-IL-23p19 antikorları.
JP5592792B2 (ja) 2007-09-26 2014-09-17 ユセベ ファルマ ソシエテ アノニム 二重特異性抗体の融合体
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
CN102272154A (zh) 2008-10-29 2011-12-07 惠氏有限责任公司 单域抗原结合性分子的纯化方法
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
AU2009324354B2 (en) 2008-12-10 2016-04-14 Ablynx Nv Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
AU2009329501B2 (en) 2008-12-19 2015-11-26 Ablynx N.V. Genetic immunization for producing immunoglobulins against cell-associated antigens such as P2X7, CXCR7 or CXCR4
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2417163B1 (en) 2009-04-10 2019-02-27 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
EP3828201A1 (en) 2009-04-30 2021-06-02 Ablynx N.V. Method for the production of domain antibodies
WO2010142534A1 (en) * 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
CN102459332B (zh) 2009-06-05 2015-08-19 埃博灵克斯股份有限公司 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
HUE051430T2 (hu) 2009-07-10 2021-03-01 Ablynx Nv Eljárás variábilis domének elõállítására
EP2473527B1 (en) 2009-09-03 2016-11-30 Ablynx N.V. Stable formulations of polypeptides and uses thereof
EP2486056A1 (en) 2009-10-09 2012-08-15 Ablynx N.V. Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
GB201000467D0 (en) * 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
CN102753148B (zh) 2010-02-11 2018-01-26 埃博灵克斯股份有限公司 用于制备气雾剂的方法和组合物
AP2012006359A0 (en) * 2010-03-03 2012-08-31 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
EP2563814A1 (en) 2010-04-30 2013-03-06 Ablynx N.V. Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine il-23
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
CN103154035B (zh) 2010-05-27 2017-05-10 根马布股份公司 针对her2的单克隆抗体
EP2575880B1 (en) 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
DE102010026061A1 (de) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-markiertes Peptid zur Detektion eines Tumors, der einen Her2/neu-Rezeptor exprimiert
AU2011277983C1 (en) * 2010-07-16 2016-09-29 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
WO2012175400A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Serum albumin binding proteins
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012042026A1 (en) 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
DK2632946T3 (en) 2010-10-29 2018-03-12 Ablynx Nv PROCEDURE FOR MANUFACTURING VARIABLE IMMUNGLOBULIN SINGLE DOMAINS
JP5736764B2 (ja) * 2010-12-21 2015-06-17 Jnc株式会社 発光活性を有する融合蛋白質
WO2012085111A1 (en) * 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
PT2691415T (pt) 2011-03-28 2018-10-19 Ablynx Nv Método para produção de formulações sólidas compreendendo domínios variáveis únicos de imunoglobulina
CA2832389A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
EP2699260A1 (en) * 2011-04-20 2014-02-26 Genmab A/S Bispecifc antibodies against her2
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2707382B1 (en) 2011-05-09 2019-07-17 Ablynx NV Method for the production of immunoglobulin single variable domains
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP2974737A1 (en) 2011-06-23 2016-01-20 Ablynx N.V. Techniques for predicting, detecting and reducing a specific protein interference in assays involving immunoglobulin single variable domains
RU2700630C2 (ru) 2011-06-23 2019-09-18 Аблинкс Нв Методы предсказания, обнаружения и уменьшения неспецифической интерференции белков в способах анализа с использованием одиночных вариабельных доменов иммуноглобулинов
EP2723772A1 (en) 2011-06-23 2014-04-30 Ablynx N.V. Immunoglobulin single variable domains directed against ige
EP4350345A2 (en) 2011-06-23 2024-04-10 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
MX2014001883A (es) * 2011-08-17 2014-05-27 Glaxo Group Ltd Proteinas y peptidos modificados.
CA2850261C (en) 2011-09-30 2021-04-20 Ablynx Nv C-met immunoglobulin single variable domains
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN102399288B (zh) * 2011-10-19 2013-06-05 山西德丰信成生物科技有限公司 针对免疫球蛋白Fc段的单域重链抗体
DK2797957T3 (da) * 2011-11-23 2019-09-23 Medimmune Llc Bindingsmolekyler specifikke for her3 og anvendelser deraf
EP2620772A1 (en) * 2012-01-25 2013-07-31 APP Latvijas Biomedicinas petijumu un studiju centrs Gastric cancer biomarkers and methods of use thereof
EP3473708B1 (en) 2012-07-24 2021-01-27 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
EP2890720B1 (en) * 2012-08-30 2019-07-17 The General Hospital Corporation Compositions and methods for treating cancer
CA2883264A1 (en) 2012-10-15 2014-04-24 Universitat Zurich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
EP2719706A1 (en) 2012-10-15 2014-04-16 Universität Zürich Bispecific HER2 ligands for cancer therapy
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
WO2014111550A1 (en) * 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
CN105051067B (zh) 2013-03-12 2020-04-17 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
EP2994164B1 (en) * 2013-05-08 2020-08-05 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
WO2015002985A2 (en) * 2013-07-01 2015-01-08 University Of Maryland Fc coupled compositions and methods of their use
JP6721503B2 (ja) * 2013-09-26 2020-07-15 アブリンクス エン．ヴェー． 二重特異性ナノボディ
CA2931356A1 (en) 2013-11-27 2015-06-04 Zymeworks Inc. Bispecific antigen-binding constructs targeting her2
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
KR102514910B1 (ko) 2014-01-27 2023-03-29 몰레큘러 템플레이츠, 인코퍼레이션. 폴리펩티드를 전달하는 mhc 클래스 i 항원결정기
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US20170002046A1 (en) 2014-03-11 2017-01-05 Molecular Templates, Inc. Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
EP3604333B1 (en) 2014-03-11 2021-05-05 Molecular Templates, Inc. Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions capable of specifically binding cd38
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
RU2723940C2 (ru) * 2014-03-21 2020-06-18 Экс-Боди, Инк. Биспецифические антигенсвязывающие полипептиды
US11009511B2 (en) 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
RS63085B1 (sr) 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
EP3137488B1 (en) 2014-06-11 2019-01-02 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
CN112481283A (zh) 2014-07-21 2021-03-12 诺华股份有限公司 使用cd33嵌合抗原受体治疗癌症
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
KR102612313B1 (ko) 2014-07-21 2023-12-12 노파르티스 아게 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
US20180036442A1 (en) 2014-07-29 2018-02-08 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
US10851149B2 (en) 2014-08-14 2020-12-01 The Trustees Of The University Of Pennsylvania Treatment of cancer using GFR α-4 chimeric antigen receptor
JP7084138B2 (ja) 2014-08-19 2022-06-14 ノバルティス アーゲー 癌処置に使用するための抗ｃｄ１２３キメラ抗原受容体（ｃａｒ）
CN114621969A (zh) 2014-09-17 2022-06-14 诺华股份有限公司 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA40035A (fr) 2014-10-14 2016-04-21 Dana Farber Cancer Inst Inc Molécules d'anticorps de pd-l1 et leurs utilisations
JP6872482B2 (ja) 2014-11-27 2021-05-19 ザイムワークス，インコーポレイテッド Ｈｅｒ２を標的とする二重特異性抗原結合性構築物の使用方法
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
CN107406497A (zh) * 2014-12-19 2017-11-28 埃博灵克斯股份有限公司 半胱氨酸连接的纳米抗体二聚体
KR20170132749A (ko) * 2015-03-31 2017-12-04 브이에이치스퀘어드 리미티드 폴리펩티드
WO2016156465A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
CN114958764A (zh) 2015-04-08 2022-08-30 诺华股份有限公司 Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US10927186B2 (en) 2015-05-13 2021-02-23 Ablynx N.V. T cell recruiting polypeptides based on TCR alpha/beta reactivity
EP4345112A2 (en) 2015-05-13 2024-04-03 Ablynx N.V. T cell recruiting polypeptides based on cd3 reactivity
AU2016262168B2 (en) 2015-05-13 2022-06-23 Zymeworks Bc Inc. Antigen-binding constructs targeting HER2
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3325020B1 (en) * 2015-07-17 2022-01-12 Vrije Universiteit Brussel Radiolabelled antibody fragments for use in treating cancer
CN107922493A (zh) 2015-07-26 2018-04-17 分子模板公司 包含志贺毒素a亚基效应物和cd8+ t‑细胞表位的细胞靶向分子
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN105085656B (zh) * 2015-09-01 2018-04-27 中国人民解放军军事医学科学院基础医学研究所 P19/Ebi3复合物及其多克隆抗体在系统性红斑狼疮诊治中的应用
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
US10968271B2 (en) * 2015-10-30 2021-04-06 Ablynx N.V. Polypeptides against IL-23
NO2768984T3 (ja) 2015-11-12 2018-06-09
ES2905912T3 (es) 2015-11-13 2022-04-12 Ablynx Nv Dominios variables de inmunoglobulina de unión a albúmina sérica mejorados
CN108473585B (zh) 2015-11-18 2022-04-05 默沙东公司 Pd1和/或lag3结合剂
AU2016355568A1 (en) 2015-11-18 2018-06-21 Merck Sharp & Dohme Llc PD1/CTLA4 Binders
US11332519B2 (en) 2015-11-18 2022-05-17 Ablynx N.V. Serum albumin binders
KR102095140B1 (ko) 2015-11-18 2020-03-31 머크 샤프 앤드 돔 코포레이션 Ctla4 결합제
CA3007421A1 (en) 2015-12-17 2017-06-22 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US10604558B2 (en) * 2016-01-05 2020-03-31 Colorado State University Research Foundation Compositions comprising resurfaced cell-penetrating nanobodies and methods of use thereof
MA55746A (fr) 2016-01-21 2022-03-02 Novartis Ag Molécules multispécifiques ciblant cll-1
CA3016287A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
WO2017172517A1 (en) 2016-03-29 2017-10-05 Stcube & Co., Inc. Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
WO2017172518A1 (en) 2016-03-29 2017-10-05 Stcube, Inc. Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof
PL3443096T3 (pl) 2016-04-15 2023-06-19 Novartis Ag Kompozycje i sposoby do selektywnej ekspresji chimerycznych receptorów antygenowych
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
RU2765809C2 (ru) 2016-06-23 2022-02-03 Аблинкс Н.В. Усовершенствованные фармакокинетические анализы для одиночных вариабельных доменов иммуноглобулина
EP3484455A2 (en) 2016-07-15 2019-05-22 Novartis AG Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
JP2019528251A (ja) 2016-07-20 2019-10-10 エスティーキューブ，インコーポレイテッド グリコシル化ｐｄ−ｌ１に結合する抗体の組合せを使用するがんの処置および治療の方法
CN118021943A (zh) 2016-07-28 2024-05-14 诺华股份有限公司 嵌合抗原受体和pd-1抑制剂的组合疗法
KR20190036551A (ko) 2016-08-01 2019-04-04 노파르티스 아게 Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
CA3036301C (en) 2016-09-22 2021-04-20 Molecular Partners Ag Recombinant binding proteins comprising ankyrin repeat domains and their use
AR110676A1 (es) 2016-10-07 2019-04-24 Novartis Ag Tratamiento del cáncer utilizando receptores de antígenos quiméricos
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
GB201618432D0 (en) 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
KR102665596B1 (ko) 2016-11-16 2024-05-14 아블린쓰 엔.브이. Cd123 및 tcr 알파/베타에 결합할 수 있는 t 세포 동원 폴리펩티드
CN110049997B (zh) 2016-12-07 2023-09-22 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白单可变结构域
SG11201906264YA (en) 2017-01-17 2019-08-27 Ablynx Nv Improved serum albumin binders
CA3050574A1 (en) 2017-01-17 2018-07-26 Ablynx Nv Improved serum albumin binders
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
JP7186401B2 (ja) * 2017-02-28 2022-12-09 フエー・イー・ベー・フエー・ゼツト・ウエー タンパク質の経口送達のための手段及び方法
CN106866823A (zh) * 2017-03-08 2017-06-20 康众（北京）生物科技有限公司 一种抗Her2的纳米抗体
CN110546506B (zh) 2017-03-31 2023-04-04 埃博灵克斯股份有限公司 改进的免疫原性测定法
EP3609580A4 (en) * 2017-04-09 2021-03-24 Combio Pharmaceutical, Inc. BIPARATOPIC AND MULTIPARATOPIC ANTIBODIES WITH COMMON LIGHT CHAIN AND METHOD OF USE
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3643726A4 (en) 2017-06-20 2021-09-01 Nanomab Technology Limited ANTI-HER2 NANOCBODIES, CODING SEQUENCE AND ASSOCIATED USE
CN109096396B (zh) * 2017-06-20 2022-01-04 华兰生物工程股份有限公司 一种抗pd-l1人源化纳米抗体及其应用
AU2018290237A1 (en) 2017-06-22 2020-01-16 Novartis Ag Antibody molecules to CD73 and uses thereof
AU2018292618A1 (en) 2017-06-27 2019-12-19 Novartis Ag Dosage regimens for anti-TIM-3 antibodies and uses thereof
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
CN111278858A (zh) 2017-07-11 2020-06-12 指南针制药有限责任公司 结合人cd137的激动剂抗体及其用途
US20200172617A1 (en) 2017-07-20 2020-06-04 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
KR20200089286A (ko) 2017-11-16 2020-07-24 노파르티스 아게 조합 요법
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
CA3082280A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
JP7383617B2 (ja) 2017-12-28 2023-11-20 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｐｄ－ｌ１に対する抗体及びそのバリアント
AU2019205128A1 (en) * 2018-01-04 2020-07-16 Lumosa Therapeutics Co., Ltd. Single-domain antibody-cytosine deaminase fusion proteins
JP7366908B2 (ja) 2018-01-15 2023-10-23 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｐｄ－１に対する単一ドメイン抗体及びその変異体
US20210038659A1 (en) 2018-01-31 2021-02-11 Novartis Ag Combination therapy using a chimeric antigen receptor
JP7266611B2 (ja) 2018-02-26 2023-04-28 アブリンクス・エヌ・フェー ペプチドリンカーをコードする改良されたヌクレオチド配列
EP3765495A1 (en) * 2018-03-13 2021-01-20 Smivet B.V. Single domain antibodies binding to tetanus neurotoxin
SG11202006674QA (en) 2018-03-30 2020-08-28 Nanjing Legend Biotech Co Ltd Single-domain antibodies against lag-3 and uses thereof
JPWO2019198731A1 (ja) * 2018-04-10 2021-04-22 国立大学法人東北大学 抗体断片及び該抗体断片を含む二重特異性抗体
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
EP3573652A1 (en) 2018-04-17 2019-12-04 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
TW202003580A (zh) 2018-05-21 2020-01-16 美商坎伯斯治療有限責任公司 用於增強nk細胞對標靶細胞之殺死之組合物及方法
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3806962A1 (en) 2018-06-13 2021-04-21 Novartis AG Bcma chimeric antigen receptors and uses thereof
US20210238268A1 (en) 2018-06-19 2021-08-05 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
AU2019358419A1 (en) 2018-10-08 2021-04-15 Universität Zürich HER2-binding tetrameric polypeptides
CN113166269A (zh) 2018-11-13 2021-07-23 指南针制药有限责任公司 对抗检查点分子的多特异性结合构建体及其用途
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
MX2021007391A (es) 2018-12-20 2021-09-23 Novartis Ag Regimenes de baja dosis extendida para inhibidores de mdm2.
KR20210129671A (ko) 2019-02-15 2021-10-28 노파르티스 아게 3-(1-옥소-5-(피페리딘-4-일)이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
EP3927371A1 (en) 2019-02-22 2021-12-29 Novartis AG Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
JP7308477B2 (ja) * 2019-03-11 2023-07-14 パナソニックＩｐマネジメント株式会社 抗体、複合体、それを用いた検出装置及び検出方法
SG11202110732XA (en) 2019-03-29 2021-10-28 Atarga Llc Anti fgf23 antibody
JP2022538083A (ja) * 2019-06-21 2022-08-31 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
JP2022537780A (ja) 2019-06-21 2022-08-29 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
CN110499259B (zh) * 2019-07-22 2021-07-27 浙江工业大学 一种解酯耶氏酵母yw100-1及其应用
TW202128775A (zh) 2019-10-16 2021-08-01 英商阿法克塔生命科學有限公司 PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
BR112022007179A2 (pt) 2019-10-21 2022-08-23 Novartis Ag Inibidores de tim-3 e usos dos mesmos
TW202128166A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 組合療法
JP2023503163A (ja) 2019-11-26 2023-01-26 ノバルティス アーゲー キメラ抗原受容体及びその使用
BR112022009799A2 (pt) 2019-12-06 2022-08-16 Ablynx Nv Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina alvejando tnfalfa e il-23
EP4077389A1 (en) 2019-12-20 2022-10-26 Novartis AG Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
CN114980902A (zh) 2020-01-17 2022-08-30 诺华股份有限公司 用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合
CN115298322A (zh) 2020-01-17 2022-11-04 贝克顿迪金森公司 用于单细胞分泌组学的方法和组合物
JP7481856B2 (ja) * 2020-02-25 2024-05-13 シスメックス株式会社 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
MX2022012376A (es) * 2020-03-31 2023-02-15 Biotalys NV Polipeptidos antifungicos.
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
US20230270872A1 (en) 2020-06-24 2023-08-31 Sapreme Technologies B.V. Conjugate of saponin and single-domain antibody, pharmaceutical composition comprising said conjugate, therapeutic use thereof
WO2021259507A1 (en) 2020-06-24 2021-12-30 Sapreme Technologies B.V. Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
JP2023541763A (ja) 2020-06-24 2023-10-04 サプリーム テクノロジーズ，ベー．フェー． Ｖｈｈを含むａｄｃ又はａｏｃと、サポニン又はリガンド－サポニンコンジュゲートとを含む組み合わせ
CN116322782A (zh) 2020-06-24 2023-06-23 萨普雷米科技有限公司 单结构域抗体、皂苷和效应分子的缀合物，包含其的药物组合物，所述药物组合物的治疗用途
KR102486958B1 (ko) * 2020-07-08 2023-01-11 한국과학기술원 인간 상피세포 증식인자 수용체 2형의 도메인 4에 특이적으로 결합하는 신규 폴리펩티드 및 이의 용도
TW202216761A (zh) 2020-07-16 2022-05-01 瑞士商諾華公司 抗β細胞素抗體、其片段及多特異性結合分子
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
WO2022031870A1 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. IL27Rα BINDING MOLECULES AND METHODS OF USE
WO2022043558A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204021A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022098771A1 (en) * 2020-11-03 2022-05-12 Ab Studio Inc. Multispecific antibodies and uses thereof
US20240002509A1 (en) 2020-11-06 2024-01-04 Novartis Ag ANTIBODY Fc VARIANTS
CA3198447A1 (en) 2020-11-13 2022-05-19 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
MX2023007299A (es) 2020-12-18 2023-07-04 Ablynx Nv Polipeptidos de reclutamiento de celulas t basados en la reactividad de tcr alfa/beta.
US20240076403A1 (en) * 2020-12-18 2024-03-07 Simcere Zaiming Pharmaceutical Co., Ltd. Her2 antibody and application thereof
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
WO2022177392A1 (ko) 2021-02-19 2022-08-25 (주)샤페론 Cd47에 대한 단일 도메인 항체 및 이의 용도
KR20220118962A (ko) 2021-02-19 2022-08-26 (주)샤페론 Pd-l1에 대한 단일 도메인 항체 및 이의 용도
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
EP4365203A1 (en) * 2021-07-01 2024-05-08 Ningbo T-MAXIMUM Biopharmaceuticals Co., Ltd. Antigen-binding polypeptide targeting b7h3 and application thereof
EP4367130A1 (en) 2021-07-09 2024-05-15 Luxembourg Institute of Health (LIH) Dimeric protein complexes and uses thereof
IL310221A (en) 2021-07-19 2024-03-01 Regeneron Pharma IL12 receptor agonists and methods of using them
US11970548B2 (en) * 2021-08-27 2024-04-30 Innovative Cellular Therapeutics Holdings, Ltd. Nanobody target GCC and uses in chimeric antigen receptor cell therapy
CN113813380B (zh) * 2021-09-15 2023-03-07 深圳大学 一种靶向her2的光热纳米材料及其制备方法与应用
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
WO2023057567A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Pd-l1 binding affimers
WO2023070317A1 (zh) * 2021-10-26 2023-05-04 江苏省农业科学院 基于dc细胞的双功能纳米抗体及其构建方法和应用
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023121447A1 (en) 2021-12-22 2023-06-29 Sapreme Technologies B.V. Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
US20230383010A1 (en) 2022-02-07 2023-11-30 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
WO2023183317A2 (en) * 2022-03-21 2023-09-28 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof
TW202405007A (zh) * 2022-04-15 2024-02-01 美商瓦利托爾有限公司 人類化多價蛋白質結合物
CN114805578B (zh) * 2022-05-06 2022-12-06 浙江大学 一种白细胞免疫球蛋白样受体亚家族b成员2的羊驼纳米抗体、制备方法及其应用
WO2023218243A1 (en) 2022-05-12 2023-11-16 Avacta Life Sciences Limited Lag-3/pd-l1 binding fusion proteins
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023230488A1 (en) * 2022-05-23 2023-11-30 Cereius, Inc. Her2-binding agents and uses thereof
CN114920839B (zh) * 2022-06-17 2023-03-10 天津大学 特异性结合il-23的纳米抗体及其用途
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
WO2024094165A1 (zh) * 2022-11-04 2024-05-10 茂行制药(苏州)有限公司 靶向b7h3的通用型car-t细胞及其制备方法和应用
CN116574186B (zh) * 2023-07-07 2023-11-28 云南大学 特异性结合her2的纳米抗体及其应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821337A (en) * 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US20050266000A1 (en) * 2004-04-09 2005-12-01 Genentech, Inc. Variable domain library and uses
WO2006008548A2 (en) * 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20100135998A1 (en) * 2007-02-28 2010-06-03 Schering Corporation Combination therapy for treatment of immune disorders
US20110028695A1 (en) * 2007-11-27 2011-02-03 Hilde Adi Pierrette Revets Method for obtaining polypeptide constructs comprising two or more single domain antibodies

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572654B2 (en) 1984-05-11 1988-05-12 Premier Submers-A-Lite Pty. Ltd. Tail light assembly
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5038508A (en) 1989-08-08 1991-08-13 Brown Frank C Safety device for a firearm
ATE163675T1 (de) 1989-12-22 1998-03-15 Hoffmann La Roche Zytotoxischer lymphozyten-reifefaktor
DE69112207T2 (de) 1990-04-05 1996-03-28 Roberto Crea "walk-through"-mutagenese.
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
EP0640130B1 (en) 1992-05-08 1998-04-15 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
ES2162823T5 (es) 1992-08-21 2010-08-09 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
EP0698097B1 (en) 1993-04-29 2001-08-16 Unilever N.V. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DE69738166T2 (de) 1996-06-27 2008-06-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
AU744302B2 (en) 1997-10-31 2002-02-21 Beth Israel Deaconess Medical Center Use of anti-IL-12 antibodies in transplantation rejection
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
JP2003525016A (ja) 1998-02-19 2003-08-26 エクサイト セラピーズ， インコーポレイテッド リンパ球活性化を調節するための組成物および方法
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2000040968A1 (en) 1999-01-05 2000-07-13 Unilever Plc Binding of antibody fragments to solid supports
EP1144616B2 (en) 1999-01-19 2009-01-14 Unilever Plc Method for producing antibody fragments
AU779162B2 (en) 1999-02-05 2005-01-06 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
DE60035163T2 (de) 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
SI2168984T1 (sl) 1999-03-25 2012-12-31 Abbott Gmbh & Co. Kg Človeška protitelesa za vezavo IL-12 in postopki izdelave
EP1169453A1 (en) 1999-04-22 2002-01-09 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
IL147022A0 (en) 1999-06-18 2002-08-14 Cv Therapeutics Inc Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1
CN101121021B (zh) * 1999-06-25 2011-12-07 杰南技术公司 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗
WO2001009300A2 (en) 1999-08-02 2001-02-08 Keygene N.V. Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
HU230679B1 (en) 1999-09-09 2017-08-28 Merck Sharp & Dohme Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
WO2001044301A1 (en) 1999-11-29 2001-06-21 Unilever Plc Immobilized single domain antigen-binding molecules
AU1859201A (en) 1999-11-29 2001-06-12 Unilever Plc Immobilisation of proteins
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
ATE428733T1 (de) 2000-03-14 2009-05-15 Unilever Nv Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
HUP0300369A2 (hu) 2000-04-11 2003-06-28 Genentech, Inc. Többértékű antitestek és alkalmazásuk
CA2441903C (en) 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2001286405B2 (en) 2000-07-31 2007-05-10 Yale University Innate immune system-directed vaccines
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
EP2706116A1 (en) 2001-01-17 2014-03-12 Emergent Product Development Seattle, LLC Binding domain-immunoglobulin fusion proteins
WO2002076489A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1433793A4 (en) * 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
CA2471116A1 (en) 2001-12-21 2003-07-03 Serge Muyldermans Method for cloning of variable domain sequences
JP2005517674A (ja) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
AU2003227504A1 (en) * 2002-04-15 2003-10-27 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
EP1382615A1 (en) 2002-07-15 2004-01-21 Xerion Pharmaceuticals AG MCAM inhibitors
PL214010B1 (pl) 2002-07-15 2013-06-28 Genentech Inc Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala
AU2003284891A1 (en) 2002-10-23 2004-05-13 Ludwig Institute For Cancer Research A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
CA2505325C (en) 2002-11-08 2014-02-25 Ablynx N.V. Stabilized single domain antibodies
EP1558650A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
WO2005044858A1 (en) 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
PT1570267E (pt) 2002-12-03 2012-01-03 Ucb Pharma Sa Ensaio para a identificação de células produtoras de anticorpos
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
ATE444984T1 (de) 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
CA2511838C (en) 2002-12-31 2014-05-06 Schering Corporation Uses of mammalian cytokine; related reagents
WO2004062551A2 (en) 2003-01-10 2004-07-29 Ablynx N.V. RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
JP4791960B2 (ja) 2003-06-27 2011-10-12 バイオレン，インク． ルックスルー突然変異誘発
CA2535550A1 (en) 2003-08-12 2005-03-03 William M. Yarbrough Treatment for acne vulgaris and method of use
ES2385829T3 (es) 2003-08-20 2012-08-01 Ucb Pharma, S.A. Métodos para obtener anticuerpos
AU2005215527B2 (en) 2004-02-17 2011-04-07 Merck Sharp & Dohme Corp. Methods of modulating IL-23 activity; related reagents
JP4550470B2 (ja) 2004-04-14 2010-09-22 住友電装株式会社 コネクタ
US20050279676A1 (en) 2004-06-21 2005-12-22 Izzy Zuhair A Fluid filter assembly for a dispensing faucet
JP4939410B2 (ja) 2004-07-06 2012-05-23 バイオレン，インク． 強化された特性を持つ変性ポリペプチドを発生させるためのルックスルー変異誘発
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
DE102004051767B4 (de) 2004-07-20 2018-03-29 Witte-Velbert Gmbh & Co. Kg Getriebeanordnung zum Öffnen/Schließen einer Tür, einer Klappe o. dgl.
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
KR20070084170A (ko) 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
WO2006040154A2 (en) 2004-10-14 2006-04-20 Dublin City University Prokaryotic two hybrid system
WO2006068987A2 (en) 2004-12-20 2006-06-29 Schering Corporation Uses of il-23 antagonists in the treatment of diabetes mellitus
BRPI0515858A (pt) 2004-12-21 2008-08-12 Centocor Inc anticorpos anti-il-12, epìtopos, composições, métodos e usos
CA2595682A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
HUE045710T2 (hu) 2005-05-18 2020-01-28 Ablynx Nv Javított, alfa tumor nekrózis faktor elleni nanobodies
BRPI0609797B8 (pt) * 2005-05-20 2021-05-25 Ablynx Nv nanocorpos melhorados para o tratamento de desordens mediadas por agregação
CN103145838A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
CN101370525B (zh) 2005-08-19 2013-09-18 Abbvie公司 双重可变结构域免疫球蛋白及其用途
CA2619052A1 (en) 2005-08-25 2007-03-01 Eli Lily And Company Anti-il-23 antibiodies
EP2116258A1 (en) * 2005-09-01 2009-11-11 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
WO2007042289A2 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
KR101210395B1 (ko) * 2005-12-29 2012-12-11 얀센 바이오테크 인코포레이티드 인간 항-ｉｌ-23 항체, 조성물, 방법 및 용도
AU2007209201A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
AU2007237501A1 (en) 2006-04-14 2007-10-25 Ablynx N.V. DP-78-like nanobodies
CA2671581A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
AU2009324354B2 (en) * 2008-12-10 2016-04-14 Ablynx Nv Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821337A (en) * 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
US6818749B1 (en) * 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US20050266000A1 (en) * 2004-04-09 2005-12-01 Genentech, Inc. Variable domain library and uses
WO2006008548A2 (en) * 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20100135998A1 (en) * 2007-02-28 2010-06-03 Schering Corporation Combination therapy for treatment of immune disorders
US20110028695A1 (en) * 2007-11-27 2011-02-03 Hilde Adi Pierrette Revets Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US20110053865A1 (en) * 2007-11-27 2011-03-03 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US20110059090A1 (en) * 2007-11-27 2011-03-10 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110028695A1 (en) * 2007-11-27 2011-02-03 Hilde Adi Pierrette Revets Method for obtaining polypeptide constructs comprising two or more single domain antibodies
US20110053865A1 (en) * 2007-11-27 2011-03-03 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US20110059090A1 (en) * 2007-11-27 2011-03-10 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US8975382B2 (en) 2007-11-27 2015-03-10 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
US9969805B2 (en) 2007-11-27 2018-05-15 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2015160940A1 (en) * 2014-04-15 2015-10-22 President And Fellows Of Harvard College Bi-specific agents
WO2017015623A3 (en) * 2015-07-23 2017-03-23 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins
US10093742B2 (en) 2015-07-23 2018-10-09 Inhibrx, Inc. Multispecific GITR-binding fusion proteins and methods of use thereof
US10844129B2 (en) 2015-07-23 2020-11-24 Inhibrx, Inc. Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids
US11866507B2 (en) 2017-04-11 2024-01-09 Inhibrx, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same

Also Published As

Publication number Publication date
US9969805B2 (en) 2018-05-15
CA2706425A1 (en) 2009-06-04
WO2009068627A2 (en) 2009-06-04
AU2008328784B2 (en) 2014-03-27
JP2011504740A (ja) 2011-02-17
EP2650311A3 (en) 2014-06-04
CN101970490A (zh) 2011-02-09
EP2220120A2 (en) 2010-08-25
AU2008328784A1 (en) 2009-06-04
AU2008328785A1 (en) 2009-06-04
EP2650311A2 (en) 2013-10-16
IL205734A0 (en) 2010-11-30
CA2706200A1 (en) 2009-06-04
US20110053865A1 (en) 2011-03-03
EP2215125A1 (en) 2010-08-11
US8975382B2 (en) 2015-03-10
AU2008328781A1 (en) 2009-06-04
CA2705890A1 (en) 2009-06-04
WO2009068627A3 (en) 2009-10-01
US20110059090A1 (en) 2011-03-10
WO2009068631A1 (en) 2009-06-04
WO2009068625A2 (en) 2009-06-04
US20110028695A1 (en) 2011-02-03
US20150232562A1 (en) 2015-08-20
EP2225278A2 (en) 2010-09-08
WO2009068628A1 (en) 2009-06-04
MX2010005783A (es) 2010-08-10
BRPI0819656A2 (pt) 2015-06-23
WO2009068625A3 (en) 2009-08-06
EP2215123A1 (en) 2010-08-11
KR20100097716A (ko) 2010-09-03
ZA201004057B (en) 2011-04-28
WO2009068630A1 (en) 2009-06-04
AU2008328779A1 (en) 2009-06-04
AU2008328779B2 (en) 2014-06-05
CA2706675A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
US20110189203A1 (en) Immunoglobulin constructs
US10808032B2 (en) Biological materials related to HER3
Caravella et al. Design of next-generation protein therapeutics
JP2022105085A (ja) 改変ｊ鎖を有する結合分子
US20160009824A1 (en) Tetravalent bispecific antibodies
JP2009529339A (ja) Ｉｌ−６を標的とするアミノ酸配列およびそれを含みｉｌ−６介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド
JP2010527597A (ja) 骨疾患及び骨障害の治療のために、ｒａｎｋ−ｌに指向性を有するアミノ酸配列及びこれを含むポリペプチド
WO2013064701A2 (en) Bispecific antibodies and methods for isolating same
US20220251220A1 (en) N-TERMINAL scFv MULTISPECIFIC BINDING MOLECULES
CN111683963B (zh) 半胱氨酸工程化的抗原结合分子
JP2012518400A (ja) 多価および／または複数特異的ｒａｎｋｌ結合性構築物
El Khatib et al. The mosaic puzzle of the therapeutic monoclonal antibodies and antibody fragments-A modular transition from full-length immunoglobulins to antibody mimetics
AU2015264802B2 (en) Biological materials related to HER3
TW202330596A (zh) 經修飾的蛋白或多肽
Jin et al. The Design and Engineering of IgG-Like Bispecific Antibodies

Legal Events

Date Code Title Description
AS Assignment

Owner name: ABLYNX N.V., BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HERMANS, GUY;REVETS, HILDE ADI PIERRETTE;SAUNDERS, MICHAEL JOHN SCOTT;SIGNING DATES FROM 20100616 TO 20101014;REEL/FRAME:025164/0071

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION